Q2 FY2026 EarningsQ2 FY26 results were significantly above consensus, primarily driven by a top-line beat of $9.24M vs. $3.63M expected and a GAAP net income of $16.9M, largely boosted by a $43.8M one-time gain from debt extinguishment. Diluted EPS of -$0.08 beat the consensus mean of -$0.1367. The reacquisition of worldwide seralutinib rights and a successful Pre-NDA Type B meeting with the FDA position the company for an NDA submission in September 2026, though cash runway remains tight into Q1 FY27.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Gossamer Bio(GOSS) the Revenue is 9.238 M (-19.59%), Beat estimate;the EBIT is -26.07 M (+32.74%), Beat estimate;the EPS is 4 (+129.4%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B19.59%
0.00B68.41%
+0.01B48.82%
EBITExceed expectations
-0.03B32.74%
-0.03B16.81%
+0.01B15.93%
EPSExceed expectations
4129.41%
-10.933319.61%
+14.9333109.80%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf